Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2521 to 2535 of 8235 results

  1. V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]

    Awaiting development Reference number: GID-TA11881 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Suspected Cancer: recognition and referral (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 2 February 2026.

    NICE guideline
    In consultation

  3. Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia ID6519

    In development Reference number: GID-TA11649 Expected publication date:  14 October 2026

    Technology appraisal guidance
    In development

  4. Adalimumab for treating early Dupuytren's contracture [ID6276]

    Awaiting development Reference number: GID-TA11363 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Familial Breast Cancer: initial assessment and genetic testing (update)

    In development Reference number: GID-NG10438 Expected publication date:  22 April 2027

    NICE guideline
    In development

  6. Artificial Intelligence assisted echocardiography to support diagnosis of heart failure: Early Value Assessment

    In development Reference number: GID-HTE10067 Expected publication date:  19 May 2026

    Health technology evaluations
    In development

  7. Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881) [ID6496]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment

    In development Reference number: GID-HTE10065 Expected publication date:  02 April 2026

    Health technology evaluations
    In development

  9. Digital technologies to support self-management of asthma: early value assessment

    In development Reference number: GID-HTE10063 Expected publication date:  17 April 2026

    Health technology evaluations
    In development

  10. Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment: draft guidance

    We are listening to your views on this Health technology evaluation. Comments close 21 January 2026.

    Health technology evaluation
    In consultation

  11. Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]

    In development Reference number: GID-TA11502 Expected publication date:  02 December 2026

    Technology appraisal guidance
    In development

  12. Tarlatamamb for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]

    In development Reference number: GID-TA11812 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Rare diseases: quality standard consultation

    We are listening to your views on this Quality standard. Comments close 20 January 2026.

    Quality standard
    In consultation

  14. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]

    Awaiting development Reference number: GID-TA11538 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]

    In development Reference number: GID-TA11660 Expected publication date: TBC

    Technology appraisal guidance
    In development